With reformulated shots from Pfizer and Moderna on the horizon, the F.D.A. has decided that Americans under 50 should wait to receive second boosters.
Mayor Eric Adams says that offering immediate prescriptions to people who test positive at the mobile sites will help address concerns over inequities in distributing antiviral treatments.
Dr. Anthony Fauci, President Biden’s top pandemic adviser, sought to discourage doubts about the antiviral drug Paxlovid following what appeared to be a “rebound” of Covid-19 after taking the pills.
The vaccines seem safe for children and are likely to protect against severe illness. But data on efficacy are thin, and most children have already been infected.
A recommendation from the C.D.C. director would be the final step before doses are rolled out for the roughly 20 million children under the age of 5.
Some scientists believe that a clearer picture of Covid vaccine efficacy could have emerged sooner if investigators had tracked certain immune cells, not just antibodies.
Covid vaccines for young children are finally coming.
States have already ordered millions of doses; if the agency authorizes them in the coming days, babies, toddlers and preschoolers could start receiving shots next week.
Outside experts will make their recommendations this week on how the agency should rule on applications from Pfizer and Moderna to vaccinate the nation’s youngest children.
A third dose would enhance immunity to the coronavirus, the agency said. But hesitancy is high, and less than one-third of children in this age group have received two doses.
Reinfection may become the norm even for people who have received several vaccine doses.
More than eight million of the 28 million children in that age group in the United States have received two vaccine shots.
Given that the age group has the lowest coronavirus vaccination rate of all eligible Americans, public health experts are not expecting a rush for the booster.
Both Moderna and Pfizer-BioNTech have asked the agency to approve their vaccines for the youngest children.
The under-5 Covid vaccine should be approved.
Once again, a dysfunctional health care system has hindered our pandemic response.
Pfizer and BioNTech will soon ask the Food and Drug Administration for emergency authorization of Covid booster doses for that age group, the companies said.
A meeting of the committee underscored how many uncertainties lie ahead, including whether a vaccine that works better against variants can be ready by fall.
People in the age group can get the additional shot at least four months after their first booster. Those 12 and older with certain immune deficiencies are also eligible.
Authorization is one step; it’ll take time to resolve confusion and hesitancy.
Federal officials appear to be coalescing around a plan to offer people 65 and older — and possibly some younger adults — the option of another booster, in case infections surge again soon.
Given the surge of Omicron cases in Asia, the new research lends urgency to vaccination campaigns in China and Hong Kong.
The company said the vaccine produced a strong immune response in children younger than 6, but proved only about 40 percent effective in preventing symptomatic Covid-19.
The move follows recalls of other medications found to have higher levels of potential carcinogens.
Experts say that the most vulnerable would benefit from a second booster soonest.
The move could further inflame a tortuous debate among scientists over when the coronavirus vaccines’ protection should be bolstered, and for whom.
Once dismissed as less effective, the vaccine now seems to be preventing infections and illness about as well as the two mRNA options.
Moderna is going head-to-head with Pfizer-BioNTech for the opportunity to vaccinate the youngest children, the only Americans still not eligible for shots.
The F.D.A. temporarily halted efforts to authorize the Pfizer-BioNTech vaccine for young children amid several unexpected findings. The coming weeks should bring clarity.
Despite so-so vaccine news for children 5-11.
The proposed settlement, which requires a judge’s approval, would resolve a legal battle that began after the company, in 2016, raised the price for two EpiPens to $608 from $100.
A Food and Drug Administration official said the best time for an additional shot may be fall, when the spread of the coronavirus is expected to pick up again
Here’s what families should know about the delay.
The agency will wait for data on whether three doses of Pfizer-BioNTech’s Covid vaccine are effective in young children after new, disappointing data.
It’s not clear whether three doses of the Pfizer-BioNTech vaccine will adequately protect young children. But the F.D.A. may authorize the first two doses anyway.
It’s confusing, but don’t freak out.
The Food and Drug Administration asked to review Pfizer’s data on two doses now, while the company continues to assess whether three doses would be more effective.
Rejected three times, Unilever suggests it will keep fighting to acquire a giant in the world of pain relievers, toothpastes and cold treatments.
Scarce supplies and surging Covid cases have caused health officials, hospitals, doctors and patients to scramble for pills and infusions.
President Biden announced that his administration would double its order of Pfizer’s scarce Covid-19 antiviral drug, which has been shown to reduce hospitalizations.
Regulators will also allow even younger children with immune deficiencies to get an extra shot.
Amid staffing shortages, companies are weighing conflicting guidance on when employees who have tested positive for the coronavirus can safely return to work.
The first-of-its-kind treatment, Paxlovid, has been found to be highly protective against severe illness. It could be available within a few days.
The treatment, called Paxlovid, is likely to work against Omicron and could be available in the United States before the end of the year.
The company’s finding is based on only a small study of blood samples in a laboratory, but others are sure to follow.
The pills must be given early in the course of infection, which means access to timely, accurate test results will be crucial.
South Africa gave the world an early warning. Decisive action on containment and surveillance could help us control it.
As infections rise, Americans over 18 will be permitted to get extra doses. But it’s not clear boosters really are needed by so many people, or that the shots will turn back the pandemic.
If the C.D.C. agrees, adults who received a second shot of the Pfizer or Moderna vaccine at least six months ago could be eligible by this weekend.